Two bespoke cell therapies developed by a small biotech firm called Iovance Biotherapeutics (IOVA) are inducing deep and durable tumor responses in patients with advanced melanoma and cervical cancer, according to updated results from clinical trials announced Friday.

The Iovance treatments, still experimental, are custom-built around immune cells called tumor infiltrating lymphocytes, or TILs. They are different from the more well-known and personalized T cell therapies called CAR-Ts that are approved to treat certain types of blood cancers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy